Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iridex/Miravant PDT For Macular Degeneration Granted FDA Expedited Review

This article was originally published in The Gray Sheet

Executive Summary

Miravant Medical Technologies and Iridex Corp. are seeking a broader indication for their photodynamic therapy laser than current offerings to treat age-related macular degeneration (AMD)
Advertisement

Related Content

Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Off-Label Photodynamic Therapy Coverage Extended To AMD Population
Off-Label Photodynamic Therapy Coverage Extended To AMD Population
Advertisement
UsernamePublicRestriction

Register

MT020472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel